Compare Nasdaq Inc (NDAQ) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Nuwellis Inc — how do they compare? Nasdaq Inc trades at $92.95 (market cap $51.63B), while Nuwellis Inc trades at $0.7 (market cap $2.20M). The key difference: Nasdaq Inc is far larger — about 23468.2× Nuwellis Inc's market cap, and Nasdaq Inc pays a 1.26% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 125 Days and Nuwellis Inc for 26 Days on average.
| NDAQ | NUWE | |
|---|---|---|
Market Cap | $51.63B | $2.20M |
Volume | 2,668,175 | 121,544 |
Sector | Financials | Health |
52-Week High | $100.98 | $146.65 |
52-Week Low | $76.85 | $0.68 |
Typical Hold Time | 125 Days | 26 Days |
Enterprise Value | $58.09B | -$1.52M |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq Inc. (NDAQ) trades at $91.93, down 0.37% on the day, with strong fundamentals including 2025 revenue of $8.26B and net income of $1.79B. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $1.02 EPS. Technical indicators show a bearish overall signal despite bullish moving averages, with key support at $90 and resistance at $92-94.
NDAQ presents a compelling investment case with 61% analyst buy ratings and a $110.43 consensus price target, representing 20% upside. Strong profitability metrics (22.5% net margin, 16.5% ROE) and growing Financial Technology business offset technical weakness. Risks include market volatility exposure and competitive pressures in exchange services.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
